New drug tested in people with liver disease – early safety check

NCT ID NCT07519135

Recruiting now Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing an investigational drug called PF-08653944 in 26 adults, some with healthy livers and others with mild to severe liver impairment. Researchers want to see how liver function affects the way the body processes the drug and whether it is safe. Participants receive a single injection and are monitored closely. The study is not expected to provide direct medical benefit but will guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-08653944 (also called MET097)
What this could lead to: If successful, this study could help determine safe dosing of PF-08653944 for people with liver disease.
What could go wrong: This is a very early Phase 1 study with only 26 participants. It is not designed to test if the drug works, only how it is processed and tolerated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Floridian Clinical Research
RECRUITING

Miami Lakes, Florida, 33016, United States
Genesis Clinical Research
RECRUITING

Tampa, Florida, 33603, United States
Orlando Clinical Research Center
RECRUITING

Orlando, Florida, 32809, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.